Estrella Immunopharma Highlights ARTEMIS® T-Cell Therapy Data Selected for ASH 2026, Demonstrating Deep and Durable Leukemia Responses and Superior Extramedullary Disease Clearance Versus Conventional CAR-T in Preclinical Models
Key Highlights
- ➤ARTEMIS achieved approximately 10,000-fold leukemia-burden reductions across AML and B-ALL models
- ➤ARTEMIS completely regressed extramedullary AML lesions with no AML cells detected in marrow
- ➤All ARTEMIS-treated mice remained alive and disease-free beyond day 100
- ➤ARTEMIS produced faster, deeper responses than antigen-matched conventional CAR-T cells
- ➤EB103 is undergoing the STARLIGHT-1 Phase I/II trial in B-cell non-Hodgkin lymphoma
Expert Statements
Cynthia Pussinen, Chief Executive Officer of Estrella Immunopharma
“While cellular immunotherapies have transformed treatment for certain hematologic cancers, disease persistence and relapse remain formidable challenges, particularly when leukemia extends beyond the bone marrow”
Cynthia Pussinen, Chief Executive Officer of Estrella Immunopharma
“What makes these findings particularly compelling is the combination of a potentially important new understanding of how extramedullary leukemia contributes to systemic disease progression and the ability of ARTEMIS T cells to achieve rapid, deep and sustained responses in these preclinical models.”
Cynthia Pussinen, Chief Executive Officer of Estrella Immunopharma
“Importantly, the investigators observed faster and deeper leukemia clearance compared with conventional CAR-T cells.”
Cynthia Pussinen, Chief Executive Officer of Estrella Immunopharma
“We believe these findings strengthen the scientific rationale for the ARTEMIS platform and reinforce the importance of advancing EB103 through clinical development.”
Cynthia Pussinen, Chief Executive Officer of Estrella Immunopharma
“Our focus remains on translating this promising science into meaningful therapeutic options for patients facing difficult-to-treat hematologic cancers.”
Estrella Immunopharma Highlights ARTEMIS(® )T-Cell Therapy Data Selected for ASH 2026, Demonstrating Deep and Durable Leukemia Responses and Superior Extramedullary Disease Clearance Versus Conventional CAR-T in Preclinical Models
Preclinical ARTEMIS AbTCR treatment achieved approximately 10,000-fold reductions in leukemia burden across models of acute myeloid leukemia and B-cell acute lymphoblastic leukemia
Get started
Create a free account to read the full story.
